HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rises over 3%; its self-developed AD treatment drug SHR-3201 injection approved to commence clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) rose over 3%, up 2.97% as of press time, at HK$47.8, with a turnover of HK$41.3491 million. On the news front, Jiangsu Hengrui Pharmaceuticals issued an announcement that recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for SHR-3201 injection, and will commence clinical trials in the near future. SHR-3201 injection is a drug independently developed by the Company for the treatment of Alzheimer's disease (AD), which can clear disease biomarkers in patients' brains and delay cognitive decline. According to searches, no similar drugs have been approved for marketing domestically or internationally. As of now, the cumulative R&D investment in SHR-3201 injection-related projects is approximately 48.8 million yuan (unaudited).